Enovis Corporation (NYSE:ENOV) is one of the 14 oversold value stocks to invest in right now, according to Insider Monkey. Despite a challenging 2025, the stock hit a 52-week low of $21.00 on January 29, 2026. Evercore ISI analyst Vijay Kumar remains bullish on ENOV, reiterating an ‘Outperform’ rating with a $40 price target after the company’s Q4 pre-announcement.

Evercore ISI acknowledged Enovis Corporation’s revenue miss but highlighted an 11% EPS beat driven by higher-margin reconstructive operations. The firm projects improved FY26 cash flow, with free cash flow conversion exceeding 25% in Q4. BTIG analyst Ryan Zimmerman also initiated coverage on ENOV with a ‘Buy’ rating and a $41 price target, citing the company’s multi-segment orthopedic strategy and potential to outperform end markets.

Enovis Corporation focuses on developing clinically differentiated orthopedic solutions across the Prevention & Recovery and Reconstructive segments. While ENOV presents investment potential, certain AI stocks may offer greater upside and lower downside risk. Investors seeking undervalued AI stocks can explore opportunities that benefit from Trump-era tariffs and the onshoring trend.

Read more at Yahoo Finance: Evercore ISI Bullish on Enovis (ENOV) Despite Weak Share Price Momentum